Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APL-1202 versus intravesical epirubicin in previously untreated intermediate-risk non-muscle invasive bladder cancer
CTR20202224Phase 3Active
- Sponsor
- Jiangsu Wuzhong Pharmaceutical
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of APL-1202 + APL-1501 in bladder cancer, sponsored by Jiangsu Wuzhong Pharmaceutical. Started Sep 2021; status: active.
02
Drugs
APL-1202 + APL-1501
03
Conditions
bladder cancer
Beyond the preview
Go deeper on CTR20202224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202224.